Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Patients with hepatitis C virus (HCV) and cirrhosis can develop high-risk gastroesophageal varices (GEV) after sustained virological response (SVR). Surveillance is especially recommended in those with GEV before antiviral treatment.
Clinical trials evaluating seladelpar for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) have been halted after atypical histological findings were observed in a phase 2b study in NASH patients.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).